Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 4:68:e220506.
doi: 10.20945/2359-4292-2022-0506.

Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment

Affiliations

Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment

Andre Ywata de Carvalho et al. Arch Endocrinol Metab. .

Abstract

Objective: Despite a favorable prognosis, some patients with papillary thyroid carcinoma (PTC) develop recurrence. The objective of this study was to examine the impact of the combination of initial American Thyroid Association (ATA) risk stratification with serum level of postoperative stimulated thyroglobulin (s-Tg) in predicting recurrence in patients with PTC and compare the results with an assessment of response to initial therapy (dynamic risk stratification).

Subjects and methods: We retrospectively analyzed 1,611 patients who had undergone total thyroidectomy for PTC, followed in most cases (87.3%) by radioactive iodine (RAI) administration. Clinicopathological features and s-Tg levels obtained 3 months postoperatively were evaluated. The patients were stratified according to ATA risk categories. Nonstimulated thyroglobulin levels and imaging studies obtained during the first year of follow-up were used to restage the patients based on response to initial therapy.

Results: After a mean follow-up of 61.5 months (range 12-246 months), tumor recurrence was diagnosed in 99 (6.1%) patients. According to ATA risk, recurrence was identified in 2.3% of the low-risk, 9% of the intermediate-risk, and 25% of the high-risk patients (p < 0.001). Using a receiver operating characteristic curve approach, a postoperative s-Tg level of 10 ng/mL emerged as the ideal cutoff value, with positive and negative predictive values of 24% and 97.8%, respectively (p < 0.001). Patients with low to intermediate ATA risk with postoperative s-Tg levels < 10 ng/mL and excellent response to treatment had a very low recurrence rate (<0.8%). In contrast, higher recurrence rates were observed in intermediate-riskto high-risk patients with postoperative s-Tg > 10 ng/mL and indeterminate response (25%) and in those with incomplete response regardless of ATA category or postoperative s-Tg value (38.5-87.5%). Using proportion of variance explained (PVE), the predicted recurrence using the ATA initial risk assessment alone was 12.7% and increased to 29.9% when postoperative s-Tg was added to the logistic regression model and 49.1% with dynamic risk stratification.

Conclusion: The combination of ATA staging system and postoperative s-Tg can better predict the risk of PTC recurrence. Initial risk estimates can be refined based ondynamic risk assessment following response to therapy, thus providing a useful guide for follow-up recommendations.

Keywords: Thyroid; papillary thyroid carcinoma; recurrence; risk assessment; thyroglobulin.

PubMed Disclaimer

Conflict of interest statement

Disclosure: no potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1. Participant flowchart. PTC: papillary thyroid carcinoma; ATA: American Thyroid Association; s-Tg: stimulated thyroglobulin.
Figure 2A
Figure 2A. Response after initial therapy according to American Thyroid Association risk category and postoperative stimulated thyroglobulin (sTg) level in patients with papillary thyroid carcinoma.
Figure 2B
Figure 2B. Response after initial therapy according to the combination of American Thyroid Association risk category and postoperative stimulated thyroglobulin (sTg) level in patients with papillary thyroid carcinoma.
Figure 3
Figure 3. Time-dependent receiver operating characteristic curve for the prediction of disease-free survival using postoperative stimulated thyroglobulin (s-Tg) in patients treated for papillary thyroid carcinoma. AUC: area under the curve: PPV: positive predictive value: NPV: negative predictive value.
Figure 4
Figure 4. Influence of American Thyroid Association (ATA) initial risk stratification and postoperative stimulated thyroglobulin (s-Tg) level on the probability of recurrence-free survival in patients treated for papillary thyroid carcinoma. (A) Kaplan Meier survival based on ATA initial risk stratification. (B) Kaplan Meier survival based on s-Tg level. Note that the difference in recurrence risk is not statistically significant between patients with s-Tg ≤ 1 and 1-10 ng/mL (P=0.09). (C) Kaplan Meier survival according to the combination of ATA initial risk stratification and s-Tg (< or ≥ 10 ng/mL).

Similar articles

References

    1. Wiltshire JJ, Drake TM, Uttley L, Balasubramanian SP. Systematic Review of Trends in the Incidence Rates of Thyroid Cancer. Thyroid. 2016 Nov;26(11):1541–1552. doi: 10.1089/thy.2016.0100. - DOI - PubMed
    1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments] Cancer. 1998 Dec 15;83(12):2638–2648. doi: 10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1. - DOI - PubMed
    1. Grogan RH, Kaplan SP, Cao H, Weiss RE, Degroot LJ, Simon CA, et al. A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery. 2013 Dec;154(6):1436–1446. doi: 10.1016/j.surg.2013.07.008. discussion 1446-7. - DOI - PubMed
    1. Guo K, Wang Z. Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis. Int J Clin Exp Pathol. 2014 Aug 15;7(9):5393–5403. - PMC - PubMed
    1. Vaisman A, Orlov S, Yip J, Hu C, Lim T, Dowar M, et al. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck. 2010 Jun;32(6):689–698. doi: 10.1002/hed.21371. - DOI - PubMed